Meeting
2017 ASCO Annual Meeting
Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome.
Authors
Jeffrey S. Weber
Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
Jeffrey S. Weber , Rupal Ramakrishnan , Andressa Laino , Anders E. Berglund , David Woods
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3031)
DOI
10.1200/JCO.2017.35.15_suppl.3031
Abstract #
3031
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.
First Author: Andrea Forschner
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi
Poster
2021 ASCO Annual Meeting
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
First Author: Oleh Kobziev